Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

RAS (Rat Sarcoma Virus)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

‹

OncoGuide™ EpiLight™ Methylation Detection Kit

OncoGuide™ EpiLight™ Methylation Detection Kit

›

RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1	trastuzumab + tucatinib Sensitive: A1 - Approval trastuzumab + tucatinib Sensitive : A1
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pyrotinib Sensitive: C3 – Early Trials trastuzumab + pyrotinib Sensitive : C3	trastuzumab + pyrotinib Sensitive: C3 – Early Trials trastuzumab + pyrotinib Sensitive : C3
RAS wild-type + HGF elevation	Colorectal Cancer	RAS wild-type + HGF elevation	Colorectal Cancer	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3	cetuximab Resistant: C3 – Early Trials cetuximab Resistant : C3
RAS wild-type + BRAF wild-type + MAP2K1 N57K	Colorectal Cancer	RAS wild-type + BRAF wild-type + MAP2K1 N57K	Colorectal Cancer	panitumumab Resistant: C3 – Early Trials panitumumab Resistant : C3	panitumumab Resistant: C3 – Early Trials panitumumab Resistant : C3
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3	trastuzumab + pertuzumab Sensitive: C3 – Early Trials trastuzumab + pertuzumab Sensitive : C3
MSI-H/dMMR + RAS mutation	Colorectal Cancer	MSI-H/dMMR + RAS mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
RAS wild-type + BRAF wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + BRAF wild-type + HER-2 positive	Colorectal Cancer	trastuzumab + pyrotinib Sensitive: C3 – Early Trials trastuzumab + pyrotinib Sensitive : C3	trastuzumab + pyrotinib Sensitive: C3 – Early Trials trastuzumab + pyrotinib Sensitive : C3
RAS wild-type + HER-2 amplification	Colorectal Cancer	RAS wild-type + HER-2 amplification	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
RAS wild-type + HER-2 overexpression	Colorectal Cancer	RAS wild-type + HER-2 overexpression	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
HER-2 overexpression + RAS wild-type	Colorectal Cancer	HER-2 overexpression + RAS wild-type	Colorectal Cancer	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3	EGFR inhibitor Resistant: C3 – Early Trials EGFR inhibitor Resistant : C3
RAS wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + HER-2 positive	Colorectal Cancer	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3	pyrotinib Sensitive: C3 – Early Trials pyrotinib Sensitive : C3
RAS wild-type + BRAF wild-type + HER-2 positive	Colorectal Cancer	RAS wild-type + BRAF wild-type + HER-2 positive	Colorectal Cancer	lapatinib Sensitive: C4 – Case Studies lapatinib Sensitive : C4	lapatinib Sensitive: C4 – Case Studies lapatinib Sensitive : C4